• The secondary objectives of this study are to compare the effects of rosuvastatin 10mg with atorvastatin 10mg in subjects with metabolic syndrome, after 6weeks of treatment, on:
• Bringing subjects to their established NCEP ATP III target goals for LDL-C
• Bringing subjects to their non-HDL target goal(based on NCEP-ATP III criteria)
• Modifying other lipids and lipid ratios
• Modifying inflammatory markers
• Glucose and insulin resistance
• Safety

• The secondary objectives of this study are to compare the effects of rosuvastatin 10mg with atorvastatin 10mg in subjects with metabolic syndrome, after 6weeks of treatment, on:
• Bringing subjects to their established NCEP ATP III target goals for LDL-C
• Bringing subjects to their non-HDL target goal(based on NCEP-ATP III criteria)
• Modifying other lipids and lipid ratios
• Modifying inflammatory markers
• Glucose and insulin resistance
• Safety

The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment.

Inclusion Criteria:

• Metabolic syndrome patient; Presence of 3 or more of the following:

  • Abdominal obesity (waist circumference): men > 90cm(36 inch), women > 80cm(32 inch)
  • Triglycerides ≥ 150 mg/dL (1.70 mmol/L)
  • HDL-C: men < 40 mg/dL (1.04 mmol/L), women < 50 mg/dL (1.3 mmol/L)
  • BP ≥130/≥85 mmHg or subject receiving anti-hypertensive treatment
  • Fasting blood glucose 110 mg dL (6.11 mmol/L) - 125 mg/dL (6.94 mmol.L)

• Elevated LDL-C concentrations reported within 4 weeks of visit 1 as follows;

  • ≥ 130 mg/dL (3.36 mmol/L) to < 220 mg/dL (5.69 mmol/L) in statin naive subjects (subjects who have not taken any lipid-lowering therapy known to affect LDL-C in the 4 weeks prior to visit 1)
  • ≥ 100 mg/dL (2.59 mmol/L) to < 160 mg/dL (4.14 mmol/L) in subjects who have taken a lipid lowering drug(s) within 4 weeks of visit 1
• Triglyceride levels < 400 mg/dL (4.52 mmol/L)
• Women of childbearing potential should be using a medically acceptable form of chemical or mechanical contraception.

Exclusion Criteria:

• History of known diabetes mellitus
• Use of anti-hyperglycaemic medication.
• History of serious or hypersensitivity reactions to HMG-CoA reductase inhibitors, in particular history of myopathy.
• No CHD or CHD Risk Equivalents and 0-1 Risk factors and Framingham 10-Year risk is <10%.
• History of heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia).
• Active arterial disease such as unstable angina pectoris, myocardial infarction, transient ischaemic attack (TIA), cerebrovascular accident (CVA), coronary artery bypass surgery (CABG) or angioplasty within 2 months prior to entry in the dietary lead in period
• Uncontrolled hypothyroidism defined as thyroid stimulating hormone (TSH) > 1.5 times the upper limit of normal (ULN) at Visit 2 or subjects whose thyroid replacement therapy was initiated within 3 months of entry into dietary lead-in phase.
• Current active liver disease (alanine aminotransferase [ALT] > 2 x ULN) or severe hepatic impairment.
• Unexplained serum CK >3 times ULN (e.g. not due to recent trauma, intramuscular injections, heavy exercise, etc).
• Serum creatinine > 176 umol/L (2.0 mg/dL)
• History of alcohol, or drug, abuse or both.